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Abstract
Background: We investigated the association between heart rate and its variability with the parameters that assess
vascular, renal and cardiac target organ damage.
Methods: A cross-sectional study was performed including a consecutive sample of 360 hypertensive patients
without heart rate lowering drugs (aged 56 ± 11 years, 64.2% male). Heart rate (HR) and its standard deviation
(HRV) in clinical and 24-hour ambulatory monitoring were evaluated. Renal damage was assessed by glomerular
filtration rate and albumin/creatinine ratio; vascular damage by carotid intima-media thickness and ankle/brachial
index; and cardiac damage by the Cornell voltage-duration product and left ventricular mass index.
Results: There was a positive correlation between ambulatory, but not clinical, heart rate and its standard deviation
with glomerular filtration rate, and a negative correlation with carotid intima-media thickness, and night/day ratio
of systolic and diastolic blood pressure. There was no correlation with albumin/creatinine ratio, ankle/brachial
index, Cornell voltage-duration product or left ventricular mass index. In the multiple linear regression analysis, after
adjusting for age, the association of glomerular filtration rate and intima-media thickness with ambulatory heart
rate and its standard deviation was lost. According to the logistic regression analysis, the predictors of any target
organ damage were age (OR = 1.034 and 1.033) and night/day systolic blood pressure ratio (OR = 1.425 and
1.512). Neither 24 HR nor 24 HRV reached statistical significance.
Conclusions: High ambulatory heart rate and its variability, but not clinical HR, are associated with decreased
carotid intima-media thickness and a higher glomerular filtration rate, although this is lost after adjusting for age.
Trial Registration: ClinicalTrials.gov: NCT01325064
Keywords: Heart rate, Hypertension, Blood pressure monitoring, ambulatory, Carotid arteries, Hypertrophy, left ven-
tricular, Kidney disease
Background
Traditionally, high heart rate (HR) at rest has been
directly associated with a risk of cardiovascular (CV)
disorders, both in the general and in the elderly popula-
tion [1], as well as in the patients with previous diseases
[2,3]. Recently, the behavior of HR in different scenarios
has been assessed, with the conclusion that the benefi-
cial decrease in HR depends on the previous pathology
and CV risk factors of the patient [4]. Thus, HR and
blood pressure have been shown to intervene in the
development of CV complications in a synergistic man-
ner [5]. Although several studies have found an associa-
tion between HR and cardiovascular risk [6,7], which
HR value may have beneficial effects remains unclear
[8]. It also remains unclear whether resting HR has a
greater association with cardiovascular risk. As a result,
several types of measurements have been carried out to
establish the prognostic value of HR, including resting
HR, ECG computed HR, 24-hour mean HR, HR during
sleep, or HR after an exercise test [2,9]. Several authors
have found an association with microinflammatory
responses [10], while others consider that low HR varia-
bility (HRV) implies greater mortality than normal varia-
bility [11,12]. It also has been found that moderate
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kidney is one of the main target organs of arterial
hypertension, and a worsening of renal function is a
powerful predictor of cardiovascular risk [8]. Some
results have shown that heart rate is an independent
predictor for the prevalence of microalbuminuria in
hypertensive patients with cardiovascular risk factors
[14]. In addition, proteinuria values may be increased in
subjects with an elevated HR, even in normotensive
individuals [15]. The association of HR (both sleep and
awake HR) and its variability with vascular, renal and
cardiac target organ damage (TOD) in a cohort of
hypertensive patients has not been clearly established
[16,17].
T h ea i mo ft h ep r e s e n ts t u d yt h e r e f o r ew a st oa s s e s s
the association between office and ambulatory HR and
its variability with the parameters that assess the pre-
sence of vascular, renal and cardiac target organ
damage.
Methods
Study design and population
This was a cross-sectional study performed in a primary
care setting. We included 360 hypertensive patients
without heart rate lowering drugs, aged 30-80 years, and
seen in their primary care clinics between January 2008
and June 2010 through consecutive sampling. All
patients enrolled agreed to take part in the study. The
protocol was approved by an independent ethics com-
mittee of Salamanca University Hospital (Salamanca,
Spain), and all participants signed the corresponding
informed consent forms.
Sample size calculation indicated that the 360 patients
included in the study were sufficient to detect a mini-
mum correlation coefficient between heart rate or its
variability and subclinical organ damage parameters of
0.15 in a two-sided test, with a significance level of 0.05
and a power of 0.81.
Blood pressure, heart rate and heart rate variability
measurement
Clinical blood pressure and heart rate measurements
were obtained by performing three measurements of
systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP), with a validated sphygmomanometer,
OMRON M7 model (Omron Health Care, Kyoto,
Japan), following the recommendations of the ESH [18].
For the study, the mean of the last two measurements
obtained by the nurse of the research unit was used.
Ambulatory blood pressure monitoring (ABPM) was
performed on a day of standard activity with a cuff ade-
quate for the size of the patient’s arm. A control system,
the Spacelabs 90207 model (Spacelabs Healthcare, Issa-
quah, Washington, USA), was used and validated
according to the protocol of the British Hypertension
Society [19]. Of the total readings, ≥ 80% were consid-
ered valid. Furthermore, for the records to be evaluable,
at least 14 measurements were required during the day-
time period or at least seven during the night or rest
period. The monitor was scheduled to obtain blood
pressure measurements every 20 minutes during the
daytime and every 30 minutes during the rest period.
The mean and standard deviation, as a measurement of
variability of SBP, DBP, and HR of each patient, were
calculated for the total 24-h, daytime and night time
periods, and they were defined based on the diary
reported by the patient. We considered heart rate varia-
bility (HRV) as the mean of the standard deviation of
HR of each patient. Each patient completed a form spe-
cifying bedtime and wake-up time and the Spacelab was
programmed to analyze the variables recorded according
to the actual period of rest and activity.
Target organ damage (TOD) evaluation
Cardiac assessment
The electrocardiography examination was performed
with a General Electric MAC 3.500 ECG System (Nis-
kayuna, New York, USA) that automatically measures
the voltage and duration of waves and estimates the cri-
teria of the Cornell voltage-duration product (Cornell
VDP) [20] to assess LVH. LVH is defined as the vol-
tage-duration product > 2440 mm*ms. The echocardio-
graphy examination was performed by two investigators
specifically trained before the start of the study. A Sono-
site Micromax device (Sonosite Inc., Bothell, Washing-
ton, USA) with a 2.5 - 3.5 MHz linear transducer was
used, with the subjects lying down on their left sides.
The measurements were performed according to the
recommendations of the American Society of Echocar-
diography in mode M [21]. Left ventricular mass was
calculated with the Deveroux formula corrected for the
body surface to estimate the left ventricular mass index
(LVMI) [22]. According to the European Hypertension
Guideline of 2007, LVH was defined as an LVMI greater
than 125 g/m2 in men and 110 g/m2 in women [8].
Renal assessment
Kidney damage was assessed by measuring the glomeru-
lar filtration rate estimated (eGFR) by the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration)
equation [23] and proteinuria was assessed by the albu-
min/creatinine ratio following the ESH 2007 criteria [11].
Target organ damage was defined as plasma creatinine of
1.3 mg/dl or higher in men and 1.2 mg/dl or higher in
women, a eGFR below 60 ml/min or albumin/creatinine
ratio > 22 mg/gr in men and 31 mg/gr in women[8].
Assessment of carotid intima-media thickness (IMT)
Carotid ultrasonography to assess IMT was performed
by two investigators trained for this before starting the
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study began using the intraclass correlation coefficient,
which showed values of 0.974 (95%CI: 0.935 - 0.990) for
intra-observer agreement on repeated measurements in
20 subjects, and 0.897 (95%CI:0.740 - 0.959) for inter-
observer agreement. According to the Bland-Altman
analysis, the limit of inter-observer agreement was 0.022
(95%CI: -0.053 - 0.098) and the limit of intra-observer
agreement was 0.012 (95%CI: -0.034 - 0.059). A Sonosite
Micromax ultrasound device paired with a 5-10 MHz
multifrequency high-resolution linear transducer with
Sonocal software (Sonosite Inc., Bothell, Washington,
USA) was used for performing automatic measurements
of IMT for optimizing reproducibility. Measurements
were taken from the common carotid artery after the
examination of a 10-mm longitudinal section at 1 cm
away from the bifurcation. We performed measurements
of the anterior or proximal walls and of the posterior or
distal walls in the lateral, anterior and posterior projec-
tions, following an axis perpendicular to the artery to
discriminate two lines, one for the intima-blood inter-
face and the other for the media-adventitious interface.
Six measurements were obtained of the right carotid
and another six of the left carotid, using mean values
(mean IMT) and maximum values (maximum IMT) cal-
culated by the software automatically. The measure-
ments were obtained following the recommendations of
the Manheim Carotid Intima-Media Thickness Consen-
sus [24]. Mean IMT was considered abnormal if it was
above 0.9 mm or if there were atherosclerotic plaques
with a diameter over 1.5 mm or a focal increase of 0.5
mm or 50% of the adjacent IMT [8].
Evaluation of peripheral artery disease
This parameter was evaluatedu s i n gt h ea n k l e - b r a c h i a l
index (ABI) and was performed in the morning in
patients who had not consumed coffee or tobacco for at
least 8 hours prior to measurement in an ambient tem-
perature of 22-24°C. With the feet uncovered and the
patient in a supine position after 20 min of rest, the
pressure in the upper and lower extremities was mea-
sured using a portable Minidop Es-100Vx Doppler sys-
tem (Hadeco, Inc., Arima, Miyamae-ku, Kawasaki,
Japan). The probe was applied at posterior tibial artery
at an angle of approximately 60° relative to the direction
of blood flow. The transducer’s cuff was quickly inflated
on each ankle to about 30 mm Hg above the systolic
pressure, and the pressure was then allowed to descend
(by about 2 mmHg per second) until the first sound
corresponding to the systolic pressure was heard. Blood
pressure was also measured in both arms (measured
twice at 3-5 minute intervals). The ABI was calculated
separately for each foot by dividing the higher of the
two systolic pressures in the ankle by the higher of the
two systolic pressures in the arm. Target organ damage
was considered present if the ABI was lower than 0.9
[25] and missing value if ABI ≥ 1.30.
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation (SD), while qualitative variables were
expressed on the basis of their frequency distribution.
The Pearson correlation coefficient was used to estimate
the relationship between quantitative variables. The
multivariate analysis involved eighteen multiple linear
regression models with mean IMT (nine models) and
CKD-EPI (nine models) as dependent variables. We
included as independent variables, clinical HR, 24-hour
HR, awake HR, sleep HR, 24-hour HRV, awake HRV,
sleep HRV, N/D HR ratio and N/D HRV ratio, one in
each model, and age as the adjusted variable. Logistic
regression analysis was performed, including as depen-
dent variable the absence “0” or presence “1” of any
TOD and as independent variables, using the enter
method, age, gender, antihypertensive drugs, systolic N/
D (night/day) ratio, office systolic blood pressure, waist
circumference, atherogenic index (total cholesterol/
HDL-cholesterol), smoking, diabetes mellitus and 24-
hour HR in the first model and 24-hour HRV in the
second model. An a risk of 0.05 was established as the
limit of statistical significance. The SPSS/PC+ version
15.0 (SPSS Inc., Chicago, Illinois, USA) statistical pack-
age was used throughout.
Results
Table 1 shows the general characteristics of the patients,
cardiovascular risk factors, blood pressure, HR and its
variability (HRV) measured with different methods, as
well as the cardiac (18.3%), vascular (23.2%), renal
(18.0%) and overall TOD (45.0%). The patients on anti-
hypertensive drugs were the 44.7% (161) and the 89% of
these were on one or two drugs. The most commonly
prescribed being angiotensin receptor antagonists (34%)
and diuretics (33%) followed by ACE inhibitors (24%)
and dihydropyridine calcium antagonists (7%). The dia-
betics patients on drug therapy were 51 (68.9%). The
50% were on metformin, 30% on sulfonylurea and 17%
on insulin.
Tables 2 shows the correlation between clinical and
ambulatory HR and HRV and the measurements of the
parameters used to assess the presence of TOD. Age
showed a negative correlation with ambulatory HR and
HRV, but not clinical HR, for 24-hour, awake, and sleep
HR. GFR estimated with the CKD-EPI equation showed
a positive correlation with ambulatory HR (24-hour,
awake, and sleep) and HRV (sleep), whereas the albu-
min/creatinine ratio did not reach statistical significance.
Mean IMT showed a negative correlation with the
ambulatory HR and 24-hour, awake, and sleep HRV
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the measurements of HR and HRV with respect to ABI,
Cornell VDP or LVMI measured by echocardiography.
Finally, the night/day ratio (both systolic and diastolic)
showed a negative correlation with all HR and HRV
measurements, except for sleep HR and N/D HRV ratio.
These correlations were stronger in diabetics patients
and the subgroup without antihypertensive treatments
and weaker in the subgroup with antihypertensive
drugs, losing statistical significance in some of the corre-
lations of HR and HRV with IMT and systolic and dia-
stolic blood pressure night/day ratio. The statistics
signification of the association found between HR and
HRV with IMT and eFGR was lost after adjusting for
age.
Figure 1 shows the simple linear regression of IMT
and eGFR as dependent variables, and 24-hour HR and
24-hour HRV as independent variables. Of note is the
observation that for each 10-bpm increment in HR, the
IMT value decreases by 0.02 mm and the eGFR
increases by 3.24 ml/min/1.73 m
2.
According to the logistic regression analysis (Table 3),
the predictors of damage to any target organ were age
(Odds Ratio (OR) = 1.034 and OR = 1.033) and night/
day systolic blood pressure ratio (OR = 1.425 and OR =
1.512). Neither 24 HR nor 24 HRV reached statistical
significance.
Discussion
The data obtained in our study suggest that there is an
association between ambulatory, but not clinical, HR
and its variability with respect to IMT and eGFR,
whereas no association was observed with respect to
albumin/creatinine index, Cornell VDP, LVMI or ABI in
patients without heart rate lowering drugs. However,
this association is lost after adjusting for age. On the
other hand, the variable with the greatest capacity to
predict the presence or absence of target organ damage
was night/day systolic ratio, without HR or HRV reach-
ing statistical significance in the logistic regression
models.
The association found with ambulatory HR but not
with office HR could be due to white coat phenomenon
that increases and modify the basal HR in the office.
The association between HR and its variability with
respect to the development of target organ damage or
vascular conditions has not been clearly established.
Barrios et al. [26] noted that the absence of a decrease
in HR during the resting period is independently related
to mortality from any cause. In a recent metaanalysis,
Bangalore and Messerli et al. [4,27] found that in con-
trast to patients with myocardial infarction and heart
Table 1 General demographic and clinics characteristics
Variables Total (360)
Age 56 ± 11
Gender (male %) 231 (64.2%)
Smoking n (%) 89 (24.7%)
Diabetes Mellitus n (%) 74 (21.0%)
Cardiovascular disease n (%) 18 (5.0%)
BMI 28.1 ± 3.9
Waist circumference (cm) 97.6 ± 11.2
Antihypertensive drugs n (%) 161 (44.7%)
Diabetics patients on drug therapy n (%) 51 (68.9%)
Office BP (mmHg) SBP 138 ± 16
DBP 87 ± 10
HR (bpm) 74 ± 12
ABPM 24 h (mmHg) SBP 123 ± 11
DBP 76 ± 8
HR (bpm) 72 ± 9
HRV (SDHR) 10.7 ± 3.3
Awake ABPM (mmHg) SBP 127 ± 11
DBP 79 ± 9
HR (bpm) 76 ± 10
HRV (SDHR) 9.6 ± 3.3
Sleep ABPM (mmHg) SBP 112 ± 14
DBP 66 ± 9
HR (bpm) 62 ± 8
HRV (SDHR) 6.8 ± 3.4
Systolic night/day ratio 0.89 ± 0.08
Diastolic night/day ratio 0.84 ± 0.10
Night/day HR 0.82 ± 0.07
Night/day HRV 0.76 ± 0.38
Fasting glucose (mg/dl) 99 ± 30
Creatinine (mg/dl) 0.92 ± 0.20
Total Cholesterol (mg/dl) 209 ± 37
Triglycerides (mg/dl) 126 ± 78
Atherogenic index (Total Cholesterol/HDL-Cholesterol) 4.11 ± 1.13
Renal Albumin/Creatinine (mg/gr) 18 ± 79
eGFR (ml/min/1.73 m
2)8 6 ± 1 5
Heart Cornell VDP (mmxms) 1482 ± 780
LVMI (g/m
2) 108 ± 33
Vascular IMT mean (mm) 0.74 ± 0.12
left ABI 1.08 ± 0.16
right ABI 1.09 ± 0.15
Renal TOD, n (%) 58 (18.0%)
Heart TOD, n (%) 65 (18.3%)
Vascular TOD, n (%) 82 (23.2%)
Some TOD, n (%) 162 (45.0%)
Data for qualitative variables are expressed as n (%) and quantitative variables
as mean ± standard deviation. The duration of hypertension is indicated in
years. BMI: body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood
pressure; HR: Heart rate; HRV: Heart rate variability; SDHR:Heart rate standard
deviation; VDP: Voltaje-duration product; IMT: Intima-media thickness; LVMI:
Left ventricular mass index; ABI: ankle/brachial index. eGFR: estimate
glomerular filtration rate, TOD: Target organ damage, bpm: beats per minute
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increased the risk of cardiovascular events and death
among hypertensive patients. However, a review of pro-
spective studies [28] in which 6928 patients were sub-
jected to 24-hour ABPM (not treated with beta-blocking
agents), with a follow-up of more than 9 years, and ana-
lyzing morbidity-mortality according to HR, concluded
that in the general population HR predicts total mortal-
ity not caused by cardiovascular conditions (OR: 1.15
and 1.18, respectively).
Fácila et al. [17] studied a sample of 566 hypertensive
patients, assessing HR by ABPM during activity and
resting periods, and analyzing the association with the
presence of TOD. The prevalence of TOD was found to
be 12.4%, versus 46.7% in our study. The difference in
HR between awake and sleep (10 bpm) was the same as
in our study, but these authors found no association of
HR with TOD in the bivariate analysis. However, in the
logistic regression analysis they found a nighttime HR of
over 65 bpm to be associated with an increase in TOD
(OR: 2.41). Probably the higher prevalence of TOD
f o u n di nt h i ss t u d y ,a sw e l la st h ea n a l y s i so fH Rw i t h
different types of measurements, together with a higher
percentage of males and patients without treatment
influenced the differences found between the two stu-
dies. However, Cuspidi et al. [16] found that 48-h ambu-
latory HR was not associated with markers of target
organ damage in the early phases of essential
hypertension.
Gottsäter et al. [29] found a negative association in
diabetic patients between HR, its variability and IMT.
Likewise, Gautier et al. [30], in a cohort of healthy
patients and patients with vascular risk factors, found a
low heart rate to be related to a higher IMT. Thus, all
published data follow the same line and suggest that the
lower HR, assessed in different scenarios and in different
Table 2 Correlations between HR and HRV and parameters that assess target organ damage
Age Album/creatinine
index
eGFR Mean IMT ABI Cornell VDP LVIM g/m2 Systolic
night/day ratio
Diastolic
night/day ratio
Office HR -0.089 0.007 0.084 -0.053 0.001 -0.102 -0.104 -0.175† -0.190†
24 h HR -0.228† 0.059 0.196† -0.150† -0.100 -0.021 0.050 -0.133* -0.159†
Awake HR -0.222† 0.048 0.191† -0.147† -0.094 -0.028 0.051 -0.162† -0.188†
Sleep HR -0.136* 0.095 0.141† -0.053 -0.101 -0.010 0.054 0.012 0.020
24 h HRV -0.248† -0.094 0.095 -0.232† -0.052 -0.075 0.012 -0.187† -0.230†
Awake HRV -0.222† -0.088 0.071 -0.212† -0.047 -0.075 0.014 -0.095 -0.146†
Sleep HRV -0.292† -0.073 0.132* -0.252† -0.013 -0.045 0.050 -0.147† -0.131*
N/D ratio HR 0.115* 0.058 -0.071 0.130* -0.014 0.038 -0.002 0.267† 0.318†
N/D ratio HRV -0.161† -0.033 0.095 -0.107* 0.024 0.005 0.045 -0.092 -0.031
Correlations between HR and HRV and parameters that assess target organ damage (No diabetics)
Office HR -0,038 -0,029 0,039 -0,040 0,014 -0,077 -0,160 -0,174† -0,205†
24 h HR -0,174† -0,011 0,152* -0,101 -0,085 0,052 0,070 -0,157† -0,201†
Awake HR -0,168† -0,018 0,140* -0,095 -0,082 0,037 0,064 -0,192† -0,232†
Sleep HR -0,089 0,012 0,111 -0,016 -0,097 0,080 0,078 -0,004 -0,005
24 h HRV -0,205† -0,072 0,056 -0,184† -0,047 -0,062 -0,001 -0,194† -0,245†
Awake HRV -0,188† -0,071 0,045 -0,166† -0,047 -0,049 0,004 -0,089 -0,151*
Sleep HRV -0,234† -0,053 0,111 -0,222† 0,044 -0,005 0,079 -0,167† -0,152*
N/D ratio HR 0,100 0,037 -0,043 0,103 -0,024 0,066 0,007 0,277† 0,335†
N/D ratio HRV -0,113 -0,023 0,080 -0,089 0,081 0,032 0,071 -0,125* -0,049
Correlations between HR and HRV and parameters that assess target organ damage (Diabetics)
Office HR -0,299† 0,041 0,247* -0,110 -0,146 -0,173 0,173 -0,182 -0,139
24 h HR -0,519† 0,122 0,345† -0,394† -0,151 -0,218 -0,024 -0,092 -0,049
Awake HR -0,523† 0,098 0,358† -0,406† -0,160 -0,208 0,010 -0,109 -0,075
Sleep HR -0,393† 0,182 0,239* -0,245† -0,119 -0,245* -0,025 0,035 0,082
24 h HRV -0,455† -0,159 0,248* -0,444† -0,087 -0,119 0,073 -0,163 -0,174
Awake HRV -0,376† -0,145 0,181 -0,402† -0,072 -0,150 0,066 -0,110 -0,122
Sleep HRV -0,482† -0,102 0,257* -0,297* -0,087 -0,140 -0,268 0,004 0,005
N/D ratio HR 0,233* 0,127 -0,194 0,292* 0,072 -0,033 -0,048 0,249* 0,265*
N/D ratio HRV -0,276* -0,025 0,185 -0,068 -0,074 -0,035 -0,214 0,123 0,099
Office HR: Office Heart rate; 24 h HR: 24 hours Heart rate; Awake HR: Awake Heart rate; Sleep HR: Sleep Heart rate; 24 h HRV: 24 hours heart rate variability;
Awake HRV: Awake heart rate variability; Sleep HRV: Sleep heart rate variability; N/D ratio HR: night/day heart rate ratio; eGFR: estimate glomerular filtration rate;
IMT: Intima-media Thickness; ABI: ankle/brachial index; VDP: Voltage-duration product; LVMI: left ventricular mass index; * p < 0.05 † p < 0.01
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However, the results of Cuspidi et al. [16], similar to
ours, in which that association disappears after adjusting
for sociodemographic variables, makes it necessary to
interpret these findings with caution. Nevertheless, this
association was also found by Huikuri et al. [31]
between HR, HR variability, and progression of focal
atherosclerosis and they think it may be explained by
hemodynamic factors, effects of the autonomic nervous
system, or a combination of these factors. Likewise, a
dysautonomic nervous system has been described as a
possible explanation for the association between HRV
alteration and the progression of carotid atherosclerosis
[29].
Brotman et al. [32] noted an association between high
HR and a greater incidence of chronic and terminal
renal disease. They attributed this to autonomic dys-
function. However, we found a positive association
between HR and improved glomerular filtration, but not
with microalbuminury, though the prognostic value of
this observation is not clear, since the association was
lost after adjustment for age. Cuspidi et al. also found
no association between heart rate and renal organ
damage [16]. Therefore, the association of HR and renal
function assessed by GFR has not been clarified to date.
Martini et al. [33] found a low HRV to be an indepen-
dent risk factor for mortality among the general popula-
tion and among patients who have suffered acute
myocardial infarction.
They also concluded that there is a continuous nega-
tive association between left ventricular mass and HRV,
while Cuspidi et al. [16] found similar results with HR,
but was not confirmed by the multivariate analysis. In
this study, with patients without heart rate lowering
drugs, we did not find this association.
Finally, in our study the most important predictive
variable of damage to any target organ was the night/
day systolic ratio (OR = 1.418). A fact that had already
been suggested in 1997 by Mancia et al. [34], indicating
that the most promising index from ABPM seems to be
arterial pressure variability - exhibiting an independent
association with target organ damage in hypertensive
patients.
The main limitation of this study is its cross-sectional
design, which precludes longitudinal analysis between
HR, HRV and TOD. Another limitation is the selection
Figure 1 Simple linear regression of IMT and eGFR with 24-hour HR and 24-hour HRV. eGFR: estimate glomerular filtration rate; IMT:
Intima-media thickness; HR: Heart rate; HRV: Heart rate variability; bpm: beat per minute.
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consecutively with pragmatic and broad inclusion cri-
teria; thus, the study population included hypertensive
patients, some with diabetes and hyperlipidemia, and
many patients receiving drug therapy (not HR lowering
drugs). This could modify blood pressure levels and
thus limit the validity of some results. Consequently, the
heterogeneity of the sample could lead to some limita-
tions when interpreting the results, though it is quite
similar to the distribution of the general population of
hypertensive patients with some cardiovascular risk
factors.
Conclusion
In conclusion, high ambulatory HR and its variability,
but not clinical HR, were associated with a decreased
carotid intima-media thickness and a higher glomerular
filtration rate, although it was lost when adjusted for
age. We found no association of HR with albumin/crea-
tinine ratio, Cornell VDP, left ventricular mass index or
ankle/brachial index. In summary, the data from this
study indicate that the associations found between HR
and its variability with the parameters that assess target
organ damage is mediated principally by age. This
would be contrary to consider the HR as an indepen-
dent risk factor for the appearance of TOD.
However, given the discrepancies found in the litera-
ture, we consider that further prospective studies are
needed in order to determine the association between
HR and its variability with cardiovascular risk in the
early stages of hypertension and prior to the develop-
ment of TOD.
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